Haemonetics Corp HAE
We take great care to ensure that the data presented and summarized in this overview for HAEMONETICS CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding HAE
View all-
Black Rock Inc. New York, NY5.96MShares$455 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.1MShares$389 Million0.01% of portfolio
-
Neuberger Berman Group LLC New York, NY4.35MShares$332 Million0.24% of portfolio
-
Wellington Management Group LLP Boston, MA2.62MShares$200 Million0.03% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD2.2MShares$168 Million0.09% of portfolio
-
State Street Corp Boston, MA1.92MShares$146 Million0.01% of portfolio
-
Capital Research Global Investors Los Angeles, CA1.58MShares$120 Million0.02% of portfolio
-
River Road Asset Management, LLC1.4MShares$106 Million1.26% of portfolio
-
Geode Capital Management, LLC Boston, MA1.22MShares$93.2 Million0.01% of portfolio
-
Royce & Associates LP1.16MShares$88.6 Million0.84% of portfolio
Latest Institutional Activity in HAE
Top Purchases
Top Sells
About HAE
Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Insider Transactions at HAE
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jun 05
2025
|
Laurie A. Miller SVP, Human Resources |
BUY
Grant, award, or other acquisition
|
Direct |
3,195
+9.87%
|
-
|
Jun 05
2025
|
Farris Maryanne Maunsell VP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,662
+37.28%
|
-
|
May 30
2025
|
Simon, Christopher President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
26,234
-6.53%
|
$1,810,146
$69.38 P/Share
|
May 30
2025
|
Simon, Christopher President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
66,666
+14.23%
|
-
|
May 30
2025
|
James D Arecca EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,864
-17.17%
|
$404,616
$69.38 P/Share
|
May 30
2025
|
James D Arecca EVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,221
+26.35%
|
-
|
May 30
2025
|
Laurie A. Miller SVP, Human Resources |
SELL
Payment of exercise price or tax liability
|
Direct |
2,283
-8.08%
|
$157,527
$69.38 P/Share
|
May 30
2025
|
Laurie A. Miller SVP, Human Resources |
BUY
Grant, award, or other acquisition
|
Direct |
7,777
+21.59%
|
-
|
May 30
2025
|
Michelle L Basil EVP and General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
7,469
-15.02%
|
$515,361
$69.38 P/Share
|
May 30
2025
|
Michelle L Basil EVP and General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
15,554
+23.83%
|
-
|
May 16
2025
|
Farris Maryanne Maunsell VP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
800
+30.58%
|
-
|
May 16
2025
|
Laurie A. Miller SVP, Human Resources |
BUY
Grant, award, or other acquisition
|
Direct |
3,200
+13.52%
|
-
|
May 16
2025
|
Roy Galvin President, Global Plasma & BC |
BUY
Grant, award, or other acquisition
|
Direct |
6,755
+32.55%
|
-
|
May 16
2025
|
Frank Chan EVP, Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,689
+50.0%
|
-
|
May 16
2025
|
Michelle L Basil EVP and General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
5,689
+14.27%
|
-
|
May 16
2025
|
Simon, Christopher President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
21,405
+6.0%
|
-
|
May 16
2025
|
James D Arecca EVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,111
+24.48%
|
-
|
May 16
2025
|
James D Arecca EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,246
-7.75%
|
$87,220
$70.31 P/Share
|
May 16
2025
|
Michelle L Basil EVP and General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
2,157
-7.04%
|
$150,990
$70.31 P/Share
|
May 16
2025
|
Roy Galvin President, Global Plasma & BC |
SELL
Payment of exercise price or tax liability
|
Direct |
257
-3.43%
|
$17,990
$70.31 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 183K shares |
---|
Payment of exercise price or tax liability | 61.1K shares |
---|---|
Other acquisition or disposition | 39.7K shares |
Open market or private sale | 6.53K shares |